Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRAT | P43155 | 1/20 | 1.00 |
| ▸ | CPT2 | P23786 | 3/20 | 0.58 |
| ▸ | CPT1A | P50416 | 3/20 | 0.58 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.58 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712374 | 1.00 | CRAT (1.00) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL5712398 | 1.00 | CRAT (1.00) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| Hydrochloric Acid SCHEMBL10415561 | 0.81 | CRAT (0.68) | CRATCPT2CPT1ACPT1BMEN1 | |
| Hydrochloric Acid SCHEMBL10415560 | 0.81 | CRAT (0.68) | CRATCPT2CPT1ACPT1BMEN1 | |
| Hydrochloric Acid SCHEMBL10415559 | 0.81 | CRAT (0.68) | CRATCPT2CPT1ACPT1BMEN1 | |
| SCHEMBL24634587 | 0.79 | CPT2 (0.69) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL14070123 | 0.78 | CRAT (0.63) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL24634589 | 0.78 | CRAT (0.63) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL24634585 | 0.76 | CRAT (0.61) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL3679268 | 0.75 | CRAT (0.58) | CRATCPT2CPT1ACPT1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0287523-B1 | PROCESS FOR PRODUCING (-) N-ACETYLAMINOCARNITINE AND (+) N-ACETYLAMINOCARNITINE | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 1993-06-09 | — | — | EP | claimed |
| EP-0287523-A2 | Process for producing (-) N-acetylaminocarnitine and (+) N-acetylaminocarnitine | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 1988-10-19 | — | — | EP | claimed |
| EP-1581475-B1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND DERIVATIVES THEREOF FROM D-AND L-ASPARTIC ACID | SIGMA TAU IND FARMACEUTI (IT) | 2009-09-16 | — | — | EP | disclosed |
| EP-1581475-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND DERIVATIVES THEREOF FROM D-AND L-ASPARTIC ACID | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| US-6822115-B2 | VIA DIRECT HYDROLYSIS OF THE CHIRAL AMINOCARNITINE ESTER IN AN ACIDIC MILIEU TO YIELD A CHIRAL AMINOCARNITINE INNER SALT WITHOUT PURIFYING THE INTERMEDIATE PRODUCTS; PURITY OF >99%; RESOLUTION; ENZYME INHIBITOR OF CARNITINE PALMOYL TRANSFERASE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-11-23 | — | — | US | disclosed |
| WO-2004063143-A1 | SYNTHESIS FO (R) AND (S)-AMINOCARNITINE AND DERIVATIVES THEREOF FROM D-AND L-ASPARTIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-07-29 | — | — | WO | disclosed |
| EP-1194398-B1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | SIGMA TAU IND FARMACEUTI (IT) | 2003-08-27 | — | — | EP | disclosed |
| US-20030153783-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2003-08-14 | — | — | US | disclosed |
| US-20030153784-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-08-14 | — | — | US | disclosed |
| US-6528684-B1 | Blocking amino group, cyclizing to anhydride, decarbonylation lactonation, hydrolysis, dehydroxylation quaternation using trimethyl ammonium halide, converting to internal carboxylic amine salt and deblocking | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-03-04 | — | — | US | disclosed |
| EP-1194398-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001002341-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
| EP-0287523-B1 | PROCESS FOR PRODUCING (-) N-ACETYLAMINOCARNITINE AND (+) N-ACETYLAMINOCARNITINE | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 1993-06-09 | — | — | EP | disclosed |
| EP-0287523-B1 | PROCESS FOR PRODUCING (-) N-ACETYLAMINOCARNITINE AND (+) N-ACETYLAMINOCARNITINE | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 1993-06-09 | — | — | EP | disclosed |
| EP-0287523-A2 | Process for producing (-) N-acetylaminocarnitine and (+) N-acetylaminocarnitine | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 1988-10-19 | — | — | EP | disclosed |
| EP-0287523-A2 | Process for producing (-) N-acetylaminocarnitine and (+) N-acetylaminocarnitine | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 1988-10-19 | — | — | EP | disclosed |
| EP-0287523-A2 | Process for producing (-) N-acetylaminocarnitine and (+) N-acetylaminocarnitine | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153784-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | BCAT1, BCAT2, DDC | CRAT 229/4885CPT2 2181/4885CPT1A 1088/4885 |
| US-20030153783-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | BCAT1, BCAT2, DDC | CRAT 229/4885CPT2 2181/4885CPT1A 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.